|
|
Vaccine Detail
|
Tri-Tn MUC1 Glycopeptide-P30 Vaccine |
| Vaccine Information |
- Vaccine Name: Tri-Tn MUC1 Glycopeptide-P30 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 VNTR (20 aa, HGVTSAPDTRPAPGSTAPPA), Tn at T9, S15, T16 (Cai et al., 2013)
- Immunization Route: Intraperitoneal injection (i.p.)
- Description: A fully synthetic two-component antitumor vaccine composed of the MUC1 tandem-repeat glycopeptide HGVTSAPDTRPAPGSTAPPA bearing three Tn antigens at T9, S15, and T16, synthesized by SPPS and linked via a triethylene glycol spacer to the tetanus toxoid-derived universal T-helper epitope P30 (TT947–967: FNNFTVSFWLRVPKVSASHLE). P30 functions as both a T-helper epitope and built-in adjuvant, permitting administration in PBS without external adjuvant. In BALB/c mice, the vaccine elicited endpoint antibody titers of ~100,000, exceeding CFA/IFA-adjuvanted formulations and P2/P4 epitope conjugates and approaching or matching the immunogenicity of analogous BSA-conjugated vaccines. Antibodies were predominantly IgG1, IgG3, and IgM with detectable IgG2a/IgG2b, indicating a mixed Th2 and cell-mediated response. Immune sera bound MCF-7 breast cancer cells, mediated complement-dependent cytotoxicity, and recognized epitopes requiring both peptide and carbohydrate components. Three-site Tn glycosylation produced the strongest responses, and additional glycosylation within the GSTAP region enhanced immunogenicity (Cai et al., 2013).
|
| Host Response |
|
|
| References |
Cai et al., 2013: Cai H, Chen MS, Sun ZY, Zhao YF, Kunz H, Li YM. Self-adjuvanting synthetic antitumor vaccines from MUC1 glycopeptides conjugated to T-cell epitopes from tetanus toxoid. Angewandte Chemie (International ed. in English). 2013; 52(23); 6106-6110. [PubMed: 23616304].
|
|
